- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Biofield in discussions with FDA
Biofield is in discussions with the Food and Drug Administration over the protocol for a proposed limited confirmation study that would complement the company's application for premarket approval (PMA) of its Alexa 1000 breast cancer diagnostic system.
Biofield is in discussions with the Food and Drug Administration over the protocol for a proposed limited confirmation study that would complement the company's application for premarket approval (PMA) of its Alexa 1000 breast cancer diagnostic system. The FDA had previously asked Atlanta-based Biofield to resubmit its PMA, due to deficiencies in the design of the multicenter clinical trials intended to support the submission (SCAN 3/19/97).
The proposed confirmation study is expected to include no fewer than 300 to 400 patients with previously identified breast lesions, according to the company. Assuming the successful outcome of the confirmation study, Biofield intends to rely upon its original clinical trials of more than 1200 women to demonstrate safety, efficacy, and clinical utility.
Upon completion of the discussions to establish protocol for the limited confirmation study, Biofield will evaluate its options and finalize its plans for proceeding. If the company decides to go ahead with the proposed study, the enrollment phase of the study is expected to take several months, followed by data analysis. The PMA, once accepted for filing by the FDA, will continue to be regulated under expedited review, according to Biofield.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
